seen from China
seen from United States
seen from Puerto Rico
seen from United States
seen from Netherlands
seen from Albania
seen from Netherlands
seen from China
seen from Singapore
seen from Israel
seen from Netherlands
seen from Malaysia
seen from Israel
seen from United States
seen from United States
seen from Malaysia
seen from China
seen from Hungary
seen from Netherlands
seen from Brazil
Read more: http://bit.ly/2xLe2Lx
Updated Algorithm for Interpreting Pulmonary Function Tests
https://gomerblog.com/wp-content/uploads/2017/09/Updated-Algorithm-for-Interpreting-PFTs-e1505433906513.jpg
Read more on https://gomerblog.com/2017/11/pfts/?utm_source=TR&utm_campaign=DIRECT
www.gomerblog.com
Pulmonary diagnostic testing, particularly pulmonary function tests, offers a window into the health and functionality of your lungs.
Pulmonary Function Tests , GHS and Fit Test are just not words in Safety!
Pulmonary Function Tests , GHS and Fit Test are just not words in Safety!
It always seem simple and BORING right up to the time you have an incident or a long term claim on your WCB files, or OHS is pounding on your doors say please show us your prevention programs, then OH why didn’t anyone ever think or why didn’t any one mention this before!
For those of us that are all too familiar with the PFT, we understand that this test evaluates a person’s lung capacity and…
View On WordPress
What Is a Pulmonary Rituality Test?
A heaving function test helps to meter how unquestionably a patient's lungs function. This play around with will check: <\p>
€ The air volume that terminate be inhaled and exhaled from the lungs € How quickly the air can be inhaled and exhaled from the lungs € The colorlessness of the lungs and the wall of the teat € Diffusion characteristics that can remain detected in the membranes, which is what the prittle-prattle settle sell through € The degree to which the lungs will respond to physical therapy involving the chest<\p>
Pulmonary function tests are done to screen for diseases that may be there obstructive and restrictive in the like of. They and so are done to speckle out patients above him state a surgical procedure. One of these tests will almost always be done on people who are 65 wreath older, may have pulmonary disease, are overweight to a at large degree, have smoked a lot by the past, will move unrealizing as a long period of time, and are having a major operation on the small intestine or thoracic cavity. <\p>
Another reason until driving a pulmonary function test is in contemplation of check the disorder upon the patient when they need to be removed from a air tube. If the patient on a vent has a vital cram inlet the area respecting 10\ml per kilogram of body weight, homeopathic professionals all in all feature there is a great enough amount of exhaust fan reserve that the person may endure able to be extubated. Also, a reason to have a pulmonary function test is to show how much the pulmonary disease has progressed since the last examination. <\p>
The major piece of dodging tool that is used newfashioned a pulmonary function test is a spirometer. One of these restraint measure strikingly credit changes in air gauge. This electronic altimeter also measures air issue from for the lungs. A goods that is known considering a spirograph is usually hooked grow up to the spirometer. This animus measure how much the countenance moves inlet and out in relation with the patient's chest. The tracing wherewith the piece of paper is known as a spirogram. Wealthy computers will have a spirograph on a piece of paper that shows the value that was expected neighboring to the unconfuted observed probe. The spirometer has an on board memory that has what the numbers should roughly be in order to folk and women in all age groups. <\p>
For medical facilities that go on welfare the best equipment insofar as their pulmonary immediate constituent analysis pump , we believe that Medical Device Depot will supply the best equipment options at highly competitive prices. We have looked at dozens of sites, and this guy has the most complete and low price inventory. <\p>
New Post has been published on Preventive measures in Asthma
New Post has been published on http://the-asthma.com/deliberations-about-chronic-asthma-due-to-toluene-diisocyanate.html
Deliberations about Chronic Asthma Due to Toluene Diisocyanate
In the present study, 12 workers with suspected TDI asthma were evaluated by bronchial challenge to TDI. Seven persons demonstrated sensitivity to low levels of TDI (reactors), confirming isocyanate sensitization. Six of these TDI reactors were challenged months to years after removal from their workplace exposure, demonstrating that isocyanate sensitization may persist for years in the absence of further occupational exposure. These six persons had chronic asthma symptoms reduced by flovent and pulmonary disability despite long-term removal from exposure. Four workers have had persistent asthma for one to three years, and two workers have had asthma for nine and 12 years, respectively, after removal from the workplace.
The persistent asthma caused by TDI seems related to the presence of nonspecific bronchial hyperreactivity. Five of the TDI reactors had a positive methacholine challenge, one case showed a positive cold air challenge, and all of them required medication for daily control of respiratory symptoms. All six symptomatic TDI reactors with bronchial hyperreactivity showed late occurring responses to TDI challenge testing. It has been reported that antigen-induced late occurring asthmatic responses are associated with induction of nonspecific bronchial hyperreactivity. The present cases suggest that occupational exposure to TDI may result in a prolonged state of hyperreactive airways.
Five persons with consistent histories for TDI asthma had negative TDI challenge studies. Three demonstrated bronchial hyperreactivity by metha-choline challenge and may represent sensitized individuals tested with an insufficient TDI challenge dose. For example, worker 9 experienced prominent cough symptoms after his TDI challenge unaccompanied by significant airway obstruction. A longer TDI challenge exposure might have elicited bronchospasm, though this remains unconfirmed since further testing was not performed. The recent demonstration that a greater percentage of the 2,6 TDI isomer is released into the ambient air than the corresponding 2,4 TDI isomer in a polyurethane foam industry (though the original composition contained a minority of 2,6 TDI) raises the possibility that isomers of TDI may have different potentials for respiratory sensitization. Future inhalation challenge testing to TDI in the clinical laboratory may need to include a mixture of isomers to improve test sensitivity. Alternatively, the TDI nonreactors may have lost their sensitivity to TDI after removal from the workplace. If bronchial hyperreactivity persists after loss of TDI sensitivity, the worker may develop respiratory symptoms due to the presence of nonspecific airway hyperreactivity unrelated to isocyanate exposure. Some TDI nonreactors may not have been originally sensitized to TDI though their medical histories strongly suggested this diagnosis. These individual may have been sensitized to other agents in the workplace such as amines added to isocyanate mixtures as catalysts in polyurethane foam manufacturing, or to other non-cross-reactive isocyanates. Of course, individuals with pre-existing hyperreactive airways may respond to a variety of nonspecific irritants in the workplace environment without sensitization to specific workplace agents. Buy asthma inhalers online to prevent asthma development.
The persistence of pulmonary complaints eventually led the worker to recognize an association between symptoms and job exposure. Despite the association between the workplace environment, all but one worker continued their employment before increasing symptom severity, or employer recognition resulted in a change of job. Continued TDI exposure after symptom onset could be important in the persistence of bronchial sensitization in the TDI reactors, but further longitudinal studies will be needed to demonstrate this in isocyanate workers. In another occupational disease, studies of Western Red Cedar workers have shown that persons with a delayed identification of cedar asthma, and hence, continued occupational exposure, were more likely to have persistent disease following their removal from the workplace.
The form of TDI exposure may be an important factor in the sensitization process and in the general prognosis. Our previous studies have indicated that workers with asthma or bronchitis symptoms were more likely to have past exposure to multiple isocyanate spills. In the current study, four workers with positive bronchial challenges to TDI reported exposure to TDI spills. Worker 6 was drenched with TDI following an industrial accident. This one and only exposure was followed by at least 12 years of respiratory symptoms. Three TDI reactors worked with polyurethane foam injection processes using TDI or other isocyanates. The development of their pulmonary disease may have occurred after unknowingly high exposure to TDI.
Workers in the present study were forced to leave their jobs because of progressive respiratory symptoms. This finding supports reports which indicate industries using isocyanates have a high turnover rate of employees. A survey of a plant using TDI in a polyurethane foam process found over 16 percent of workers reporting previous job transfers out of an isocyanate work area because of respiratory problems believed to be due to the job. Future epidemiologic studies which do not have identification and follow-up of persons leaving or transferring out of the isocyanate work area may miss affected individuals.
In summary, six reported cases of TDI asthma documented by TDI bronchial challenge testing represent a subset of isocyanate workers who experienced persistent disease associated with nonspecific bronchial hyperreactivity and isocyanate sensitization despite removal from occupational exposure. This suggests the prognosis in TDI asthma remains guarded in some workers. Long-term prospective studies of symptomatic isocyanate workers are needed in order to fully define the extent of this problem.
Read yet more articles about asthma treatment:
Asthmatic Subjects Treated by Ventolin Inhalers
Ventolin Inhaler – Inhaler for Treatment Asthma
Start Asthma Treatment With Ventolin Inhalers
Details about Chronic Asthma Due to Toluene Diisocyanate
Allergy and Asthma Treated by Ventolin Inhaler
New Post has been published on Preventive measures in Asthma
New Post has been published on http://the-asthma.com/output-concerning-chronic-asthma-due-to-toluene-diisocyanate.html
Output Concerning Chronic Asthma Due to Toluene Diisocyanate
In seven cases, TDI asthma was documented by a positive inhalation challenge to TDI (Table 1). Results of baseline pulmonary function tests were generally normal (FEV1 and FVC 80 percent predicted and FEV1/FVC 70 percent) or perhaps mildly decreased in the study population as follows: spirometric findings were normal in five of seven reactors and four of five nonreactors. One reactor had a FEV1 of 73 percent predicted (and FEV/FVC of 33 percent); the second reactor had FEV1 of 69 percent and FVC of 74 percent predicted. One nonreactor had FEV/FVC of 67 percent. Four of the seven workers demonstrated a dual asthmatic response, two had isolated late bron-chospastic responses, and another had an immediate bronchospastic response to TDI (Fig 1). The six patients with dual or late bronchospasm on TDI challenge testing had nonspecific bronchial hyperreactivity as shown by a positive methacholine challenge (five cases) or a positive cold air challenge (one case). The worker with an immediate asthmatic response to TDI had a negative methacholine challenge on three occasions before and after a positive TDI inhalation test.
The seven TDI reactors reported being exposed to TDI for one day to ten years (mean, 1.9 years) prior to the onset of their asthma symptoms. Four were exposed to TDI for less than four months before developing asthma cured successfully by advair. The subject with only one day of known TDI exposure was exposed to very high concentrations during a spill when a hose coupling became loose and drenched him with TDI. Three additional TDI reactors gave a history of past exposure to TDI spill?.
The TDI reactors with bronchial hyperreactivity had been removed from isocyanate exposure for intervals as long as 12 years (mean 4.5 years, Table 2). The six TDI reactors with bronchial hyperreactivity related persistent respiratory symptoms and required bronchodilator. therapy during the interval of absent occupational exposure to TDI. These six individuals had been exposed to TDI for periods ranging from six weeks to two years before symptom severity or management recognition resulted in a change of job with removal from exposure. The TDI reactor with an isolated immediate bronchospastic response to TDI was removed from the workplace one week prior to inhalation testing.
Five workers showed no significant bronchospasm to TDI inhalation challenges at either the low or high dose (Table. 3). These nonreactors had been exposed to TDI for intervals ranging from one month to 16 years (mean five years). The time from TDI exposure until bronchial inhalation challenge testing was 1.2 years (range one week to three years). One of them gave a history of past exposure to TDI spills. Methacholine challenges were positive in three of these five workers. Two of these TDI nonreactors with bronchial hyperreactivity had respiratory symptoms at the time of TDI challenge testing. One of them reported experiencing protracted coughing when exposed to multiple irritants. This worker had prominent coughing but no demonstrable bronchospasm in response to his TDI inhalation challenge test. Three of the five patients were asymptomatic and were not receiving any medication at the time of their negative result on TDI challenge test.
Eight of the 12 workers had serologic measurements of specific IgE to TDI-HSA, MDI-HSA, or HDI-HSA performed by RAST testing. No significant levels of specific IgE to isocyanate-protein conjugate were demonstrated in any of these workers.
Table 1—Clinical Summary of Seven Workers with Suspected TDI Asthma and Positive TDI Bronchoprovocation Test
WorkerNo. Age Job Form of TDI Exposure Past TDI Spill AtopicStatus PulmonaryFunctionTests MethacholineChallenge Type of Response to TDI Challenge 1 61 Structuralengineer Spraying polyurethane paint containing TDI Yes No FEV-73% predicted FEV/FVC 63% Positive Late 2 44 Assembly line worker Polyurethane foam seats, dashboards, steering wheels No No Normal Positive Immediate and late 3 31 Refrigeratorassembler Polyurethane foam injection process No No Normal Positive* Immediate and late 4 37 Millwright TDI spills, clean up Yes No FEVj 69% Positive Immediate and late 5 24 Refrigerator Polyurethane foam injection process Possible (dog, cat milk allergies) Normal Positive Late 6 58 Airconditionerworker TDI spill Yes No Normal Positive Immediate and late 7 43 Molder Polyurethane paint containing TDI No No Normal Negative Immediate
Table 2—Clinical Course of Workers with TDI Asthma Documented by a Positive Inhalation Challenge Test to TDI
Worker Interval of TDI Exposure Until Symptom Onset Interval of TDI Exposure While Symptomatic Persistent Asthma Symptoms after Removal from TDI Exposure DailyMedications Interval from Termination of TDI Exposure until TDI Challenge Test I 1 mo 6 wk Yes T* + pt 2.5 yr 2 2 wk 3 mo Yes T+p 2.5 yr 3 lyr 1 yr Yes P 8 yr 4 10 yr 2 yr Yes T+p 3 mo 5 2 yr 6 mo Yes T+p 2 yr 6 1 day 1 day Yes P 12 yr 7 4 mo 8 mo No No 1 wk
Table 3—Clinical Summary of Five Workers with Suspected TDI Asthma and Negative TDI Bronchoprovocation Test
WorkerNo. Age Job Form of TDI Exposure Past TDI Spill AtopicHx MethacholineChallengeResults PersistentAsthmaSymptoms* Time Period of TDI Exposure 8 35 Spray painter Polyacrylic paint No No Positive Yes 2 yr 9 28 Assembly line worker Polyurethane foam process Yes No Positive Yes 4 yr(intermittent) 10 56 Spray painter Polyurethane Paint No No Positive No 4 yr 11 18 General plant TDI spill cleanup Yes No Negative No 1 wk 12 58 Transporter Polyurethane foam No (Allergic rhinitis, nasal polyps] Negative) No Not known
Figure 1. Percentage of change in pulmonary function among eight subjects following inhalation challenge testing to TDI. Figure shows (top to bottom) positive reactors who experienced dual (workers 4, 2, 3, and 6), late (workers 5 and 1) or immediate (worker 7) bronchospasm with a 20 percent or greater fall in FEV, following TDI challenge. A representative negative challenge to TDI (worker 8) is also shown.
New Post has been published on Preventive measures in Asthma
New Post has been published on http://the-asthma.com/details-about-chronic-asthma-due-to-toluene-diisocyanate.html
Details about Chronic Asthma Due to Toluene Diisocyanate
Toluene diisocyanate (TDI) is an important cause of occupational respiratory disease with approximately 5 percent of exposed workers developing occupational asthma in industries using TDI. There is uncertainty regarding the long-term prognosis of workers with TDI asthma once they are removed from isocyanate exposure. Recovery of asthma after removal from isocyanate exposure has been reported; however, there are reports documenting airway flow abnormalities for days to weeks after occupational exposure or bronchial challenge to TDI in sensitized individuals. Other clinical studies suggested respiratory symptoms following isocyanate exposure persist for extended periods, but TDI sensitivity was not documented in these cases by inhalation challenge testing. Since clinical history alone may be nondiscriminatory and no in vitro test has sufficient diagnostic sensitivity or specificity, controlled bronchial challenge testing remains the only way to confirm hypersensitivity to TDI. The present report reviews our experience with 12 isocyanate workers who had been removed from their occupational exposure to TDI and who were studied with a TDI inhalation challenge test. A retrospective review of the characteristics of these workers is presented in order to assess the course of their respiratory disease.
Methods and Subjects
Patients
Patients were referred to the Occupational Health Clinic for evaluation of possible TDI asthma over a five-year period from 1980 to 1985. In only 12 workers was the clinical and occupational history consistent with a diagnosis of occupational asthma due to TDI. Approximately 20 other subjects were evaluated, and the history was not consistent with a diagnosis of occupational asthma. Prevent asthma decline with ventolin. The 12 workers reported symptoms consistent with a diagnosis of TDI asthma including cough, shortness of breath, and wheezing which occurred for the first time while working with isocyanates. These symptoms worsened with continued TDI exposure and improved when the workers were completely removed from isocyanate exposure. Three workers reported significant nocturnal asthma symptoms; chest pain was a prominent symptom in one subject (4). The ages of these 12 workers ranged from 18 to 61 years and included ten men and two women. Three workers (4, 8, and 11) were current cigarette smokers; three subjects were past cigarette smokers (1, 4, and 6). There was no personal nor family history of asthma, hayfever, or other allergies prior to the onset of symptoms in ten of the 12 subjects.
Exposure to TDI was substantiated through their employers records. The workers held a wide variety of jobs which required different levels of skills, education, and training, but their exposure to TDI could be classified into three categories. Five individuals performed assembly line work with exposure to TDI used in a polyurethane foam injection process. Four workers were involved in spray painting polyurethane paints containing TDI, and three workers were exposed to TDI spills, often as a member of the cleanup crew.
Eight of these 12 workers reported persistent respiratory symptoms which required daily β-agonist bronchodilators and/or aminophylline despite leaving their occupational exposure to isocyanates. In several cases, intermittent steroids were used for past management of acute asthma during the course of their respiratory disease. No subject was receiving corticosteroids at the time of evaluation nor at any time up to four weeks before admission to the hospital. Buy asthma inhalers to get rid of asthma symptoms (for example: Advair Inhaler, Flovent Inhaler or Ventolin Inhalers)
On their initial evaluation, each worker received a physical examination, pulmonary function tests, and phlebotomy for determination of serum specific IgE to various isocyanate-protein conjugates. Three persons had evidence of mild airway obstruction, and one subject had moderate airway obstruction on their initial spirometric evaluation. The remaining individuals had normal pulmonary function test results when first seen in our clinic.
All patients were admitted to the University of Cincinnati General Clinical Research Center. Informed consent was obtained from each. The following protocol was used: day 1, history and physical exam, methacholine challenge; day 2, saline aerosol control challenge; day 3, low dose TDI challenge (10 ppb, 10 minutes); day 4, high dose TDI challenge (20 ppb, 20 minutes); and day 5, discharge. All medications not needed by the subjects were discontinued 48 hours prior to the TDI challenges. Inhaled isoetharine or metaproterenol was used if needed for control of respiratory symptoms. Theophylline and corticosteroids were not used on the bronchial challenge days unless needed to treat significant bronchospasm.
Pulmonary Function Tests
Pulmonary function tests were performed according to criteria established by the American Thoracic Society using a precalibrated Ohio Medical Company dry-rolling spirometer connected to a microprocessor. Measurement of FEV1, FVC, and flow rates were made in triplicate. The best value was chosen for analysis.
Inhalation Challenge to TDI
Inhalation challenge studies to TDI were performed using a specially designed inhalation facility for this purpose. The TDI vapors were generated by passing dry filtered air over the liquid surface of 99.6 percent 2,4-TDI. The TDI air stream leaving the generation system was diluted with another source of fresh filtered air at the chamber inlet. Different concentrations of TDI were generated by adjusting the various airflow rates. The air TDI-mixture passed into a 271 L inhalation chamber through which the patient breathed via a mouthpiece attached to the chamber. The concentration of TDI at a port next to the mouthpiece was continuously monitored by a rapid reading isocyanate recorder during and following TDI inhalation challenges. Periodic verification of TDI levels were made using the Marcali method. Serial pulmonary function tests were performed throughout day 2,3, and 4 of the study at time 10, 20, 30, 40, 60 minutes, hourly for six hours, and at 12 and 24 hours following the inhalation challenges. A positive challenge test was defined as a 20 percent fall in FEV1. No further testing was performed following a positive response to the low dose TDI challenge.
Bronchial Challenge to Detect Airways Hyperreactivity
In the majority of subjects, methacholine challenge tests were performed using a Collison nebulizer which delivered 11.94 μg methacholine per second (airflow rate 12.5 L/minute at 26 PSI; aerosol mass median aerodynamic diameter 1.10 μl with geometric standard deviation of 2.20 μ. The cumulative inspiratory time was measured using a Fairchild pressure sensor in combination with a Lafayette stop clock. Cumulative inspiratory dose of methacholine (in micrograms) delivered to the respiratory system was calculated from the cumulative inspiratory time and the known rate of methacholine delivery. The rate of breathing was controlled by coaching the patients to inspire for 5 to 6 seconds for each breath. The aerosol was inhaled via a disposable mouthpiece connected to a one-way Hans Rudolph valve.
Following baseline spirometry, the patient was given a 30-second isotonic saline challenge followed by repeat spirometry two minutes after challenge. Providing there is no reaction to saline, the first dose of methacholine is then given (usually 100 to 200 μg) followed by pulmonary function tests two minutes after exposure. A test is considered positive when there is a 20 percent or greater fall in FEV1s otherwise additional methacholine is administered until a total cumulative dose of 2,000 μg is given. Hie provocative dose corresponding to a 20 percent fall in FEV1 (PD,) is calculated by performing a linear regression of the log transformation of dose vs percentage fall in FEV1( Experience in our laboratory has shown that nearly all asthmatic patients respond to less than 2,000 μg methacholine using our generation system. Similar results have been reported by other investigators. In two subjects, a different method was employed. Five inhalations of increasing doses (2 mg/ml-25 mg/ ml) of methacholine were used until a 20 percent fall in FEV1 was reached.
A cold air challenge to assess the degree of nonspecific airway reactivity was performed in one subject according to a reported protocol. Briefly, a patient undergoes eucapnic hyperventilation with cold air (—40°C) for six minutes. A positive cold air challenge is defined as a 9 percent decrease in FEV1 when measured five and ten minutes postchallenge compared to a prechallenge FEVj measurement.
RadioaUergo8orbent Assay
A RAST procedure using methylcellulose discs coupled with TDI-HSA, PTI-HSA, MDI-HSA, and HDI-HSA was performed as previously described. A positive result was defined as percentage of binding two times that of laboratory workers with no known exposure to isocyanates.
